Novel FolRα-targeting antibody drug conjugate shows promise in recurrent epithelial ovarian cancer
Updated dose expansion data of the phase I STRO-002-GM1 study have been presented today by Ana Oaknin, Principal Investigator of the Vall d'Hebron Institute of Oncology's (VHIO) Gynecological Malignancies Group, on the ground ...
Jun 3, 2023
0
8
